Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for Ernexa Therapeutics (ERNA) over the last 14 years, with Q3 2024 value amounting to $19000.0.

  • Ernexa Therapeutics' Capital Expenditures changed N/A to $19000.0 in Q3 2024 from the same period last year, while for Dec 2024 it was $369000.0, marking a year-over-year increase of 184210.53%. This contributed to the annual value of $369000.0 for FY2024, which is 184210.53% up from last year.
  • Latest data reveals that Ernexa Therapeutics reported Capital Expenditures of $19000.0 as of Q3 2024.
  • Ernexa Therapeutics' 5-year Capital Expenditures high stood at $249000.0 for Q2 2024, and its period low was $4457.0 during Q1 2020.
  • Moreover, its 4-year median value for Capital Expenditures was $21720.0 (2020), whereas its average is $65818.2.
  • In the last 5 years, Ernexa Therapeutics' Capital Expenditures tumbled by 9874.45% in 2020 and then plummeted by 952.38% in 2023.
  • Over the past 4 years, Ernexa Therapeutics' Capital Expenditures (Quarter) stood at $12823.0 in 2020, then surged by 63.77% to $21000.0 in 2022, then decreased by 9.52% to $19000.0 in 2023, then changed by 0.0% to $19000.0 in 2024.
  • Its Capital Expenditures stands at $19000.0 for Q3 2024, versus $249000.0 for Q2 2024 and $101000.0 for Q1 2024.